Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MESO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a Mesoblast filing can feel like navigating a clinical protocol: pages of stem-cell science, FDA dialogues, and cash runway tables. If you are hunting for pipeline milestones, manufacturing risk factors, or the latest Ryoncil trial data, the company鈥檚 disclosures are uniquely dense. Stock Titan streamlines that complexity鈥攐ur AI breaks down each Mesoblast SEC filing so you can focus on whether the next catalyst really moves MESO.
Need the numbers fast? Access every document in one place, from a Mesoblast annual report 10-K simplified to the Mesoblast quarterly earnings report 10-Q filing complete with cash-burn analysis. Material event on trial read-outs? The Mesoblast 8-K material events explained section highlights it in seconds. Wondering how insiders react? Follow Mesoblast insider trading Form 4 transactions and get Mesoblast Form 4 insider transactions real-time alerts. You can even dive into the Mesoblast proxy statement executive compensation without sifting through hundreds of pages鈥擜I extracts the pay metrics that matter.
Whether you are comparing segment performance, tracking licensing revenue, or monitoring debt covenants, our platform delivers: AI-powered summaries that translate biotech jargon into plain language, real-time EDGAR updates the moment a document posts, and expert context that links clinical results to valuation. Stop skimming PDFs and start understanding Mesoblast SEC filings explained simply, including Mesoblast earnings report filing analysis and understanding Mesoblast SEC documents with AI. Everything you need鈥攅very filing type, always current鈥攐n a single, investor-focused dashboard.
Mesoblast is a commercial-stage biotech focused on allogeneic mesenchymal lineage cell therapies. The company received FDA approval in December 2024 for remestemcel-L (Ryoncil庐) to treat steroid-refractory acute graft-versus-host disease in pediatric patients and launched the product in March 2025. Since launch through June 30, 2025, Mesoblast reported net product sales of $11.3 million.
The company reported a net loss of $102.1 million for the year ended June 30, 2025 and cumulative losses of $1,010.9 million since inception. At June 30, 2025 Mesoblast held $161.6 million in cash and reported net cash usage from operations of $50.0 million for the year. Management states current cash plus forecasted Ryoncil庐 revenue are sufficient to meet operating cash needs for the next 12 months, and they expect to refinance existing borrowings within that period. The company remains dependent on third-party manufacturers, certain single-source suppliers and successful commercialization, and highlights multiple operational, regulatory and market risks that could affect future results.
FAQ
What is the current stock price of Mesoblast (MESO)?
What is the market cap of Mesoblast (MESO)?
